On-Q PainBuster with Bupivacaine for Total Knee Arthroplasty (TKA)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Total Knee Arthroplasty (TKA)
On-Q PainBuster with Bupivacaine - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare pain and other patient outcomes after total knee replacement when using a continuous wound analgesia system, versus usual methods of pain control.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Total Knee Arthroplasty (TKA)

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Post-operatively for three days then again at follow-up

Discharge from hospital
Satisfaction (patient and caregiver)
Post-operatively for three days
Narcotic medications taken
Post-operative nausea and vomiting
Post-operatively for three days then again at follow-up
Pain, measured by the 11-point numerical pain rating scale
Three days post-op (observed) then at follow-up (self-report)
Number of adverse events
Time of surgery to discharge
Length of Stay
Up to three days post-operatively
Time to first mobilization, first transfer and first 30-M walk

Trial Safety

Safety Progress

1 of 3

Other trials for Total Knee Arthroplasty (TKA)

Trial Design

2 Treatment Groups

C
1 of 2
S
1 of 2
Active Control
Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: On-Q PainBuster with Bupivacaine · No Placebo Group · N/A

S
Device
Experimental Group · 1 Intervention: On-Q PainBuster with Bupivacaine · Intervention Types: Device
C
Device
ActiveComparator Group · 1 Intervention: Usual Care · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: post-operatively for three days then again at follow-up

Who is running the clinical trial?

Capital Health, CanadaLead Sponsor
15 Previous Clinical Trials
20,035 Total Patients Enrolled
Gordon Arnett, MDPrincipal InvestigatorCapital Health, Canada

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
on January 10th I will have surgery at the Royal Alexandra Hospital on January 10th.
I was a patient of Dr
and start at 0.1 mg/kg/hour The patient is fit for continuous wound infusion of Bupivacaine without any allergies to the medication
situated on a large lot In Edmonton, in a bungalow on a large lot.
It is important to have a caregiver at home to help take care of you and your loved ones
, Spanish and some Japanese She can speak English, Spanish and some Japanese.
using mepivacaine This study investigated the use of intra-operative spinal anaesthesia using mepivacaine for labour analgesia
Aware of their cognitive state, and provides consent that is fully informed.
on the liver is a relatively safe procedure

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: October 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.